Sign In
Buy URGN
$38.24
-2.85 (-6.94%)
At Close: Jul 31, 2026
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
08:00am, Monday, 02'nd Mar 2026
Commercial launch is on-track for ZUSDURI™, the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC); net sal
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
07:55am, Monday, 02'nd Mar 2026
Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to Q1 2030
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
08:30am, Friday, 27'th Feb 2026
• EORTC Recurrence Score Analysis from the Pivotal ENVISION Trial to be Presented at the 2026 American Society of Clinical Oncology's Genitourinary Cancers Symposium (ASCO-GU 2026) PRINCETON, N.J.,
UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference
04:05pm, Tuesday, 24'th Feb 2026
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
08:00am, Monday, 23'rd Feb 2026
PRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Urogen Pharma $URGN Shares Bought by Truist Financial Corp
06:14am, Monday, 09'th Feb 2026
Truist Financial Corp increased its holdings in Urogen Pharma (NASDAQ: URGN) by 134.3% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutio
UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
08:00am, Wednesday, 04'th Feb 2026
PRINCETON, N.J., Feb. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
08:00am, Monday, 05'th Jan 2026
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally
01:19pm, Friday, 26'th Dec 2025
New York City-based Wildcat Capital Management sold 495,606 shares of UroGen Pharma in the third quarter. The shares were worth an estimated $6.79 million.
Urogen Pharma $URGN Shares Purchased by Squarepoint Ops LLC
05:04am, Sunday, 21'st Dec 2025
Squarepoint Ops LLC raised its position in Urogen Pharma (NASDAQ: URGN) by 187.8% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Com
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Friday, 05'th Dec 2025
PRINCETON, N.J., Dec. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma: Strong Potential As Zusduri Commercialization Accelerates
08:30am, Tuesday, 25'th Nov 2025
UroGen Pharma (URGN) is rated a Strong Buy, with a $33/share price target by end of 2026, driven by its proprietary RTGel technology. URGN's newly approved Zusduri targets a large bladder cancer marke
UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
08:00am, Tuesday, 25'th Nov 2025
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and speci
UroGen Pharma Ltd. (URGN) Q3 2025 Earnings Call Transcript
10:26pm, Thursday, 06'th Nov 2025
UroGen Pharma Ltd. ( URGN ) Q3 2025 Earnings Call November 6, 2025 10:00 AM EST Company Participants Vincent Perrone - Senior Director of Investor Relations Elizabeth Barrett - President, CEO & Direct
Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
10:16am, Thursday, 06'th Nov 2025
Urogen Pharma (URGN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.55 per share a year ago.
